A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacyBrent A. Williams, Armand Keating, Bertrand Routy et al.|Oncotarget|2017Cited by 187